Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Defibrotide to Prevent Veno-occlusive Disease in Pediatric Stem Cell Transplantation
2004-000592-33Phase 3Completed
- Sponsor
- Gentium
- Start
- Jan 2006
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of defibrotide in hepatic veno-occlusive disease (HVOD), sponsored by Gentium. Primary endpoint: Incidence of hepatic veno-occlusive disease by Day +30. Started Jan 2006; status: completed.
02
Drugs
defibrotide
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on 2004-000592-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000592-33.